



ARCHIVOS DE Bronconeumología

www.archbronconeumol.org



Original Article

Chronic Cough and Cerebellar Ataxia With Neuropathy and Bilateral Vestibular Areflexia Syndrome (CANVAS): Screening for Mutations in Replication Factor C Subunit 1 (*RFC1*)

Esther Palones^{a,b,*}, Vicente Plaza^{a,b}, Lidia Gonzalez-Quereda^{c,d}, Alba Segarra-Casas^{c,d}, Luis Querol^e, Federico Bertoletti^f, María José Rodríguez^d, Pía Gallano^{c,d,g}, Astrid Crespo-Lessmann^{a,b}

^a Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain

^b Department of Respiratory Medicine, Institut de Recerca Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

^c Genetics and Microbiology Department, Universitat Autònoma de Barcelona, Barcelona, Spain

^d Genetics Department, Institut de Recerca Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

^e Neuromuscular Disease Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

^f Department of Digestive Pathology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

^g Networked Biomedical Research Centre for Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain

ARTICLE INFO

Article history:
Received 21 February 2024
Accepted 27 April 2024
Available online xxx

Keywords:
Cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome (CANVAS)
Chronic cough (CC)
Refractory CC
Unexplained CC
Rydel-Seiffer fork

ABSTRACT

Introduction: A common complaint in patients is chronic cough (CC), which may be refractory (RCC) or unexplained (UCC). Recent studies point, as a possible cause of CC, to the hereditary cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome (CANVAS), with an estimated carrier prevalence of 1 in 20 000.

Aim: In patients with CC, determine the prevalence of the biallelic (AAGGG)exp mutation in replication factor C subunit 1 (*RFC1*) responsible for CANVAS, test the usefulness of the Rydel-Seiffer fork test, and evaluate patient quality of life (QoL).

Methods: Clinical and functional data were collected for the 33 included patients undergoing CC studies in our specialized unit. Performed were an etiological study of CC following European Respiratory Society recommendations, a genetic study of *RFC1* mutations, and Rydel-Seiffer fork testing to detect possible peripheral vibratory sensitivity impairment. Administered to evaluate QoL were 4 questionnaires.

Results: Prevalence of biallelic (AAGGG)exp in *RFC1* was 6.1% ($n=2$) overall, increasing to 7.1% in the RCC subgroup, and to 33.3% in the Rydel-Seiffer fork altered results subgroup. Prevalence of monoallelic (AAGGG)exp in *RFC1* was 18.2% ($n=6$) overall, rising to 50.0% ($n=2$) in the UCC subgroup.

Conclusion: Genetic screening for (AAGGG)exp in *RFC1*, and also use of the Rydel-Seiffer fork test, should be considered in specialized CC consultations for patients with RCC and UCC. Detecting possible CANVAS symptoms in CC studies would identify candidates for early genetic screening, of interest in reducing the disease burden for patients and health systems alike.

© 2024 The Authors. Published by Elsevier España, S.L.U. on behalf of SEPAR. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Chronic cough (CC), defined as cough lasting >8 weeks,¹ affects 3–12% of the general population^{2,3} and accounts for around 10% of pulmonology consultations.⁴ When the cause is not identified after a targeted study, it is classified as unexplained CC (UCC), and when the CC not respond to treatment of possible underlying cause, it is classified as refractory CC (RCC).⁵ Recently, the European Respira-

tory Society (ERS) Task Force proposed a new term to encompass both CC types, namely, cough hypersensitivity syndrome,^{5,6} clinically reflecting CC as an irritative cough that is frequently triggered by stimuli that do not normally produce cough.

A number of neurological diseases have been associated with CC, including Holmes-Adie syndrome⁷ and sensory neuropathy type 1B,⁸ although the underlying mechanism is still unknown. Recently, a rare disease called cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome (CANVAS) has been postulated as a possible cause of CC, given that CC is highly prevalent (30–97%) in patients with CANVAS.^{9–12} The most widely accepted hypothesis regarding the underlying mechanism of CC

* Corresponding author.
E-mail address: esther.palones@autonoma.cat (E. Palones).

<https://doi.org/10.1016/j.arbres.2024.04.028>

0300-2896/© 2024 The Authors. Published by Elsevier España, S.L.U. on behalf of SEPAR. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

is an alteration of the sensory innervation of the C fibres in both the upper respiratory tract and oesophagus, leading to the hypersensitivity that favours the development of CC.^{9,13,14} Various studies of patients with CANVAS also report gastroesophageal reflux (GER),^{9,13,15–17} suggesting that early alteration of esophageal motility may be the possible cause of GER and, in turn, of CC.

The relevance of CC for patients with CANVAS is that CC seems to precede the onset of neurological symptoms by years, and even decades.^{13,15,18} Therefore, given the possibility of early diagnosis of a progressively disabling neurological syndrome, genetic screening and counselling is important. The genetic cause of CANVAS, an hereditary autosomal recessive disease is, in most cases, the presence of biallelic expansion of the AAGGG repeat motif (AAGGG)_{exp} in intron 2 of replication factor C subunit 1 (*RFC1*).¹⁰ It has also been reported that CANVAS may exceptionally be due to (AAGGG)_{exp} and a truncating variant (nonsense or frameshift),^{19–21} or (AAAGG)_{exp} when repeats are >500.²² Further alleles involved have also recently been identified (AGGGC, AAGGC and AGAGG).²² Early diagnosis is clearly important in terms of improving quality of life (QoL) for the patient and reducing the CC burden for the health system.^{23,24}

While the precise prevalence of CANVAS is unknown, allelic frequency in (AAGGG)_{exp} in *RFC1* is estimated at 0.7% of the healthy population.¹⁰ Prevalence of biallelic carriers is therefore estimated as approximately 1 in 20 000 births,¹⁰ and, since CC is a common symptom of CANVAS, a higher prevalence would be expected in those patients. In fact, that was what was observed in the study by Guilleminault et al.,²⁵ which is, to our knowledge, the only study to date that has analyzed repeat expansion in *RFC1* in patients with RCC; those authors found that 16.2% and 8.8% of patients had biallelic and monoallelic expansion, respectively. Subsequent publications raise the possibility of including genetic screening as part of RCC and UCC studies^{12,26}; however, more research is needed to replicate and expand on available results, including, for example, for patients with respiratory pathologies²⁶ and patients with CC undergoing a protocolized study.

This study is one of the first screens for *RFC1* mutations in patients with CC describing patient clinical and functional characteristics and evaluate their QoL. Furthermore, it is the first to evaluate use of the Rydel-Seiffer fork in patients with CC to detect possible peripheral vibratory sensitivity impairment, which could be a warning sign to suspect CANVAS.

Methods

Study design and population

Cross-sectional descriptive study that included consecutively recruited patients of both sexes aged 40–90, and undergoing CC studies in a specialized hospital unit in Spain. CC was defined as cough lasting >8 weeks. Excluded were active smokers and patients who had given up smoking in the previous 12 months, patients taking angiotensin-converting enzyme inhibitors, and patients with a confirmed CANVAS diagnosis or with neurological symptoms indicative of CANVAS.

Methodology

Genetic study of biallelic (AAGGG)_{exp} in *RFC1*

A peripheral blood sample was obtained from all patients for a genetic study of *RFC1* mutations, differentiating between monoallelic and biallelic repeat motifs of (AAAAG)_{exp}, (AAAGG)_{exp}, and (AAGGG)_{exp}. DNA underwent two amplification procedures: (1) amplification by standard polymerase chain reaction (PCR) with primers flanking the intron 2 fragment of the *RFC1* gene (flanking

PCR), and (2) amplification by repeat-primed (RP) PCR in 3 independent reactions, namely, RP-PCR1 to detect the (AAAAG)₁₁ and (AAAAG)_{exp} alleles, RP-PCR2 to detect the (AAAGG)_{exp} allele, and RP-PCR3 to detect the pathological (AAGGG)_{exp} allele. Note that flanking PCR can only amplify alleles of normal size, not alleles that contain large expansions, regardless of their composition. The reference sequence used was NM.002913.4.

Rydel-Seiffer fork

Vibratory sensitivity has traditionally been studied using the standard tuning fork, which was adapted by Rydel and Seiffer in 1903 as an 8-point quantitative scale.²⁷ In our study, patients were tested by placing the Rydel-Seiffer fork on the first metatarsophalangeal joint. Patients with a result of 6 or less – considered impairment (the patient has less peripheral vibration sensitivity than expected) – were referred to neurology.

Aetiology study

The aetiology study was carried out following ERS recommendations.²⁸ All patients underwent thoracic imaging, radiography or computed tomography (CT). Spirometry was performed (Datapir-600 device; Sibelmed SA, Barcelona, Spain) following American Thoracic Society (ATS)/ERS recommendations.^{29,30} Bronchodilator tests were considered positive at >10% of predicted forced expiratory volume in the first second (FEV₁) or forced vital capacity (FVC) value 15 min after administration of 4 × 100-µg doses of salbutamol.³⁰ Fraction of exhaled nitric oxide (FENO) was measured (N-6008 chemiluminescence sensor; SIR, Madrid, Spain) following ATS/ERS recommendations.³¹ A pneumoallergens prick test, performed with standardized extracts, was considered positive for papules >3 mm. Peripheral eosinophils were measured by automatic cell counting (Coulter Max-M), and immunoglobulin E (IgE) was determined by enzyme immunoassay (UNICAP, Pharmacia, Uppsala, Sweden).

Esophageal 24-h pH was measured (Digitrapper Recorder system; Medtronic, Minneapolis, USA) from a pH-impedance probe or a 1-electrode probe placed at a distance of 5 cm from the upper margin of the lower esophageal sphincter, and analyzed results (Reflux software V.6.1; Medtronic, Minneapolis, USA) were interpreted following Lyon Consensus recommendations.³² High-resolution esophageal manometry data (ManoScan system; Medtronic, Minneapolis, USA) were analyzed (ManoView ESO software V.3.3; Medtronic, Minneapolis, USA) for interpretation following the Chicago Classification V.4.0.³³

QoL impact

To determine the QoL impact of CC, patients were administered the Discrete Emotions Questionnaire (DEQ),³⁴ Leicester Cough Questionnaire (LCQ),^{35,36} Cough Severity Diary (CSD),³⁷ and European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L).^{38,39}

- (1) DEQ consists of 32 questions regarding emotions grouped into 8 states (anger, disgust, fear, anxiety, sadness, desire, relaxation, and happiness), scored on a 7-point Likert scale (1 = lowest intensity to 7 = highest intensity).
- (2) LCQ consists of 19 questions on cough impact in the previous 2 weeks grouped into 3 domains (physical, psychological, and social), scored on a 7-point Likert scale (1 = least impact to 7 = greatest impact), with the overall score obtained by summing the domain scores.
- (3) CSD consists of 7 questions on cough severity in the previous 24 h grouped according to 3 dimensions (frequency, intensity, and disruptiveness), scored on an 11-point Likert scale (0 = lowest severity to 10 = greatest severity).

(4) EQ-5D-5L part 1 consists of 5 questions on 5 QoL domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) with 5 response options, from no problems to extreme problems (variable depending on the reference population, in our case Spanish³⁸), resulting in a health state index (where 0 is equivalent to death) scored between <0 (worse than death and 1 (full health). EQ-5D-5L part 2 is a visual analogue scale (VAS) which the patient uses to rate their perceived health (0 = worst imaginable health to 100 = best imaginable health).

Ethical and legal aspects

The study complies with the principles of the Declaration of Helsinki (18th World Medical Assembly, 1964) and was approved by the Ethics Committee of our hospital (IIBSP-TOS-2020-143) and has been registered with clinicaltrials.gov (NCT04703595).

Statistical analysis

Descriptive reference values are reported as frequencies and percentages for qualitative data, and as means and standard deviation (SD) for quantitative data. For the qualitative variables, independent proportions were compared using Pearson's Chi-square or Fisher's exact test; for quantitative variables, given that one of the groups included <10 patients, means were compared using the non-parametric Mann-Whitney *U* test.

Statistical significance was set to 5% ($\alpha=0.05$), and statistical analyses were performed with SPSS version 25 (SPSS Inc., Chicago, IL, USA).

Results

Patient clinical and functional characteristics

Included were 33 patients (Table 1), 30.3% ($n=10$) men, with a mean age of 66 (± 12) years; 57.7% ($n=19$) were ex-smokers since an average of 25.3 (± 12.9) years previously. The most frequent comorbidities were symptoms compatible with GER (60.6%; $n=20$) and arterial hypertension (AHT) (48.5%; $n=16$). CC was dry in 69.7% ($n=23$) of the patients. Overall, mean CC duration was 11.2 (± 11.6) years and mean age at CC onset was 54.8 (± 13.9) years. In the biallelic (AAGGG)exp subgroup, mean CC duration was longer and mean age at CC onset was lower, at 25.0 (± 7.1) years and 42.0 (± 16.9) years, respectively. No statistically significant differences were found between patients with and without (AAGGG)exp in *RFC1* (Table 1).

Genetic and Rydel-Seiffer fork studies

Of the 33 included patients, 2 (6.1%) had biallelic (AAGGG)exp in *RFC1*, indicating early-stage CANVAS, i.e., although their only symptom currently is CC, in the future they will develop other neurological symptoms. Another 6 (18.2%) were heterozygous carriers of (AAGGG)exp, the significance of which is as yet unknown; however, 1 heterozygous carrier had the combination (AAAGG)exp/(AAGGG)exp, which has recently been described as potentially causing CANVAS if the (AAAGG)exp motif is very large (>500 repeats).²²

The Rydel-Seiffer fork test result was altered in 22.2% ($n=6$) of the patients, and of those, 33.3% ($n=2$) were the patients with early-stage CANVAS (Table 2).

Aetiology study

No chest X-ray alterations were evident in most patients (96.7%, $n=29$); detected in 1 patient were known and oncologically mon-

itored pulmonary nodules diagnosed as tumourlets. Chest CT was normal in 46.9% ($n=15$) of the patients, and in the remaining patients, the most frequent alterations were chronic bronchopathy (18.8%; $n=6$), air trapping (15.6%; $n=5$), and emphysema (12.5%; $n=4$). Mean spirometry values were within the normal range; when studied case by case, only 1 patient (3.0%) showed obstruction, which was moderate (FEV₁/FVC, 61; FEV₁, 67%; FVC, 79%). Mean FENO was 25.5 (± 31) ppb, and was only significantly elevated in 1 patient (133 ppb). The prick test was positive in 25.8% ($n=8$) of patients. High-resolution esophageal manometry, performed in 20 of 33 patients, revealed motility impairment in 75% ($n=15$), most frequently, ineffective esophageal motility (40%; $n=8$) and $\geq 50\%$ ineffective waves (20%; $n=4$). Esophageal 24-h pH monitoring revealed pathological GER in 45% ($n=9$) of the patients. Statistically significant differences were only found in the chest CT results on comparing the groups with and without (AAGGG)exp in *RFC1* ($p=0.03$) (Table 3).

The most frequent causes of CC were GER (36.4%; $n=12$), asthma (15.2%; $n=5$), and tracheomalacia (12.1%; $n=4$). While CC resolved after study and with appropriate treatment in 15.2% ($n=5$) of the included patients, it persisted in the remaining 84.8% ($n=28$) patients, 72.7% ($n=24$) and 12.1% ($n=4$) with RCC and UCC, respectively. Prevalence of biallelic (AAGGG)exp in *RFC1* was 7.1% ($n=2$) in the RCC subgroup, 0% ($n=0$) in the UCC subgroup, and 33.3% ($n=2$) in the subgroup with altered Rydel-Seiffer fork results (see Table 2). Note that the 2 cases of early-stage CANVAS had RCC secondary to GER.

QoL study

QoL questionnaire were administered to 27 patients. Mean DEQ scores signalled anxiety 3.8 (± 1.8) and anger 3.5 (± 1.9), followed by fear 2.8 (± 1.9), disgust 2.7 (± 1.7), and sadness 2.6 (± 1.8). The mean LCQ overall score was 12.4 (± 4.8), with the social 4.1 (± 1.6) and psychological 4.2 (± 1.8) dimensions showing the highest scores. The mean overall CSD score was 5.6 (± 11.1), with frequency having the greatest impact, at 4.1 (± 2.4). Finally, the mean EQ-5D-5L part 1 score was 0.9 (± 0.1), and the mean part 2 (VAS) score was 62.5 (± 24.9). Patients with biallelic (AAGGG)exp scored worst in all 4 QoL studies, while heterozygous (AAGGG)exp carriers had similar score to the patients without that mutation in *RFC1* (Table 4).

Discussion

Ours is one of the first studies that screens for *RFC1* mutations in patients undergoing CC studies. The fact that we did not differentiate at study outset between patients with RCC, UCC, or CC resolved after treatment has made it possible to identify which patients should undergo genetic screening, namely, those in the RCC and UCC subgroups. Our study is also the first to demonstrate the usefulness of Rydel-Seiffer fork results for patient selection for genetic screening, suggesting that this test could be used as criterion for onward referral when genetic screening is not available in all specialized CC consultations (and specially for patients with an altered Rydel-Seiffer fork test), whether in the centre itself or through a referral circuit.

Detecting *RFC1* mutations as a means of early diagnosis of CANVAS is important to determine a possible underlying cause of CC that have been classified as UCC. As for future treatments for CANVAS, while there is as yet no cure, some of the symptoms can be treated, using for instance, gabapentin. Genetic diagnosis is important to avoid unnecessary examinations in individuals at risk. Identifying the genetic cause in a family's index case makes it possible to identify other family members at risk of developing or transmitting the disease to their offspring. Furthermore, in the case

Table 1
Clinical and functional characteristics of patients with chronic cough (CC) without and with biallelic or monoallelic (AAGGG)exp in *RFC1*.

	Total (n = 33)	(AAGGG)exp in <i>RFC1</i>		
		Without (n = 25)	Monoallelic (n = 6)	Biallelic (n = 2)
Clinical and functional characteristics				
Men, n (%)	10 (30.3)	8 (32.0)	1 (16.7)	1 (50.0)
Age, years (SD)	66 (±12.0)	65.2 (±11.7)	69 (±15.2)	67 (±9.9)
BMI, kg/m ² (SD)	27.6 (±4.8)	27.9 (±5.3)	69.7 (±13.0)	71.0 (±16.9)
Ex-smokers, n (%)	19 (57.7)	16 (64.0)	2 (33.3)	1 (50.0)
Comorbidities				
GER symptoms, n (%)	20 (60.6)	15 (60.0)	4 (66.7)	1 (50.0)
AHT, n (%)	16 (48.5)	12 (48.0)	3 (50.0)	1 (50.0)
Dyslipidemia, n (%)	16 (48.5)	10 (40.0)	5 (83.3)	1 (50.0)
Rhinitis, n (%)	14 (42.4)	10 (40.0)	2 (33.3)	2 (100)
Depression, n (%)	9 (27.3)	7 (28.0)	0 (0.0)	2 (100)
Obstructive sleep apnea, n (%)	7 (21.2)	5 (20.0)	2 (33.3)	0 (0.0)
Tracheomalacia, n (%)	4 (12.1)	2 (8.0)	2 (33.3)	0 (0.0)
Diabetes mellitus, n (%)	3 (9.1)	2 (8.0)	1 (16.7)	0 (0.0)
Asthma, n (%)	3 (9.1)	3 (12.5)	0 (0.0)	0 (0.0)
ILO, n (%)	3 (9.1)	1 (4.0)	1 (16.7)	1 (50.0)
COPD, n (%)	2 (6.1)	2 (8.0)	0 (0.0)	0 (0.0)
Bronchiectasis, n (%)	2 (6.1)	1 (4.0)	1 (16.7)	0 (0.0)
Fibromyalgia, n (%)	2 (6.1)	2 (8.0)	0 (0.0)	0 (0.0)
Cough characteristics				
Dry, n (%)	23 (69.7)	17 (68.0)	5 (83.3)	1 (50.0)
Onset age, mean (SD) years	54.8 (±13.9)	55.5 (±14.1)	55.8 (±12.9)	42.0 (±16.9)
Duration, mean (SD) years	11.2 (±11.6)	9.6 (±10.9)	13.7 (±13.9)	25.0 (±7.1)
Triggers				
Supine position, n (%)	13 (39.5)	8 (32.0)	4 (66.7)	1 (50.0)
Eating, n (%)	11 (34.4)	9 (36.0)	1 (16.7)	1 (50.0)
Speech, n (%)	8 (24.2)	5 (20.0)	3 (50.0)	0 (0.0)
Strong odours, n (%)	8 (24.2)	5 (20.0)	1 (16.7)	2 (100)
Stress, n (%)	8 (24.2)	7 (28.0)	0 (0.0)	1 (50.0)
Physical effort, n (%)	7 (21.2)	6 (24.0)	1 (16.7)	0 (0.0)
Temperature changes, n (%)	5 (15.2)	5 (20.0)	0 (0.0)	0 (0.0)
Associations				
Nausea, n (%)	12 (37.5)	7 (28.0)	3 (50.0)	2 (100)
Urinary incontinence, n (%)	10 (31.3)	7 (28.0)	2 (33.3)	1 (50.0)
Dyspnoea, n (%)	9 (27.3)	6 (24.0)	2 (33.3)	1 (50.0)
Dizziness, n (%)	8 (24.2)	5 (20.0)	1 (16.7)	2 (100)
Night awakenings, n (%)	7 (21.2)	4 (16.0)	1 (16.7)	2 (100)
Vomiting, n (%)	6 (18.2)	5 (20.0)	1 (16.7)	0 (0.0)
Syncope, n (%)	3 (9.1)	1 (4.0)	1 (16.7)	2 (100)
Sibilance, n (%)	3 (9.1)	2 (8.0)	1 (16.7)	0 (0.0)

Abbreviations: AHT: arterial hypertension; BMI: body mass index; COPD: chronic obstructive pulmonary disease; GER: gastroesophageal reflux; ILO: inducible laryngeal obstruction; SD, standard deviation.

* Bold signals when the 2 patients with biallelic (AAGGG)exp have the indicated clinical or functional characteristic.

Table 2
Alleles identified in patients with chronic cough, refractory chronic cough, and unexplained chronic cough, and altered peripheral vibratory sensitivity results for the Rydel-Seiffer fork test.

Genetic study		CC		RFS test, n (%) (n = 6)
Identified alleles	Interpretation	Total CC n (%) (n = 33)	RCC n (%) (n = 29)	UCC n (%) (n = 4)
(AAAAG)exp/(AAAAG)exp	CANVAS ruled out	22 (66.7)	20 (68.9)	2 (50.0)
(AAAAG)exp/(AAAGG)exp	Unknown	2 (6.1)	2 (7.1)	0 (0.0)
(AAAAG)exp/(AAGGG)exp	Heterozygous carrier	5 (15.2)	3 (10.3)	2 (50.0)
(AAAGG)exp/(AAAGG)exp	Unknown	1 (3.0)	1 (3.6)	0 (0.0)
(AAAGG)exp/(AAGGG)exp	Heterozygous carrier	1 (3.0)	1 (3.6)	0 (0.0)
(AAGGG)exp/(AAGGG)exp	CANVAS confirmed	2 (6.1)	2 (7.1)	0 (0.0)

Abbreviations: CC: chronic cough; RCC: refractory chronic cough; RFS: Rydel-Seiffer fork; UCC: unexplained chronic cough. *In bold, genetic results compatible with early CANVAS.

of CANVAS, the high frequency of carriers in the general population (0.7%)¹⁰ would indicate that genetic study is especially important in order to provide genetic and reproductive counselling to family members.

We report prevalence rates for biallelic and monoallelic (AAGGG)exp in *RFC1* of 6.1% and 18.2%, respectively, higher than estimated for the general population. Our values are largely in agreement with those reported by Guilleminault et al.,²⁵ with the difference that their biallelic expansion rate was lower, and

monoallelic expansion rate was higher, than our rates. Interestingly, that same study described only female heterozygous carriers of (AAGGG)exp in *RFC1*, whereas one of the monoallelic mutation carriers in our study was a man; a possible explanation is that we studied a broader sample of patients, including a subgroup of patients whose CC resolved after treatment, to which this male patient belonged. Regarding candidates for genetic screening, mutation prevalence was greater in patients with RCC, and was also greater in patients with UCC, but only those with monoal-

Table 3
Chronic cough: etiological study results for complementary tests.

Complementary tests	Total	(AAGGG)exp in RFC1		
		Without	Monoallelic	Biallelic
Chest X-ray	<i>n</i> = 30	<i>n</i> = 23	<i>n</i> = 6	<i>n</i> = 1
No impairment, <i>n</i> (%)	29 (96.7)	22 (95.7)	6 (100)	1 (100)
Lung tumorlets, <i>n</i> (%)	1 (3.3)	1 (4.3)	0 (0)	0 (0)
Chest CT	<i>n</i> = 32	<i>n</i> = 24	<i>n</i> = 6	<i>n</i> = 2
No impairment, <i>n</i> (%)	15 (46.9)	12 (59)	1 (16.7)	2 (100)
Chronic bronchopathy signs, <i>n</i> (%)	7 (21.9)	4 (16.7)	3 (50.0)	0 (0)
Air trapping, <i>n</i> (%)	5 (15.6)	4 (16.7)	1 (16.7)	0 (0)
Lung emphysema, <i>n</i> (%)	4 (12.5)	4 (16.7)	0 (0)	0 (0)
Ground-glass lesions, <i>n</i> (%)	2 (6.3)	2 (8.3)	0 (0)	0 (0)
Cell bronchiolitis signs, <i>n</i> (%)	1 (3.1)	0 (0)	0 (0)	0 (0)
Lung tumorlets, <i>n</i> (%)	1 (3.1)	1 (4.2)	0 (0)	0 (0)
Bronchiectasis, <i>n</i> (%)	1 (3.1)	1 (4.2)	0 (0)	0 (0)
Tracheal diverticulum, <i>n</i> (%)	1 (3.1)	0 (0)	1 (16.7)	0 (0)
Lung function tests				
<i>Spirometry</i>	<i>n</i> = 32	<i>n</i> = 24	<i>n</i> = 6	<i>n</i> = 2
FEV1/FVC, % (SD)	74.9 (±7.5)	73.7 (±7.8)	78.3 (±5.4)	79.8 (±5.5)
FEV1, % (SD)	102.4 (±19.4)	102.0 (±19.5)	107.2 (±20.8)	92.0 (±19.8)
FVC, % (SD)	107.7 (±21.5)	108.3 (±22.2)	105.5 (±18.2)	90.5 (±27.6)
<i>Bronchodilator test</i>	<i>n</i> = 27	<i>n</i> = 21	<i>n</i> = 4	<i>n</i> = 2
Positive, <i>n</i> (%)	5 (18.5)	4 (19.0)	0 (0)	1 (50.0)
<i>Methacholine test</i>	<i>n</i> = 5	<i>n</i> = 3	<i>n</i> = 2	<i>n</i> = 0
Positive, <i>n</i> (%)	1 (20.0)	1 (33.3)	0 (0)	0 (0)
FENO, ppb (SD)	25.5 (±31)	28.5 (±35.9)	12.5 (±3.5)	22.1 (±9.8)
Prick test aeroallergens	<i>n</i> = 32	<i>n</i> = 24	<i>n</i> = 6	<i>n</i> = 2
Negative, <i>n</i> (%)	23 (74.2)	17 (70.8)	5 (83.3)	2 (100)
Dust mites ^a , <i>n</i> (%)	7 (22.5)	6 (25.0)	1 (16.7)	0 (0)
Planetree, <i>n</i> (%)	2 (6.5)	2 (8.3)	0 (0)	0 (0)
Grasses, <i>n</i> (%)	1 (3.2)	1 (4.2)	0 (0)	0 (0)
Blood workup	<i>n</i> = 33	<i>n</i> = 25	<i>n</i> = 6	<i>n</i> = 2
Total IgE, kIU/L (SD)	62.3 (±93.8)	63.6 (±96.4)	74.5 (±102.9)	11.3 (±4.8)
Eosinophils, ×10 ⁹ /L (SD)	0.27 (±0.22)	0.27 (±0.22)	280 (±240.9)	260 (±282.8)
Fibreoptic bronchoscopy	<i>n</i> = 9	<i>n</i> = 8	<i>n</i> = 1	<i>n</i> = 0
No impairment, <i>n</i> (%)	2 (22.2)	2 (25.0)	0 (0)	0 (0)
Tracheomalacia, <i>n</i> (%)	5 (55.6)	4 (50.0)	1 (100)	0 (0)
ILO, <i>n</i> (%)	1 (11.1)	1 (12.5)	0 (0)	0 (0)
Lipophages > 15% or UAO, <i>n</i> (%)	2 (22.2)	2 (25.0)	0 (0)	0 (0)
Gastroscopy	<i>n</i> = 13	<i>n</i> = 10	<i>n</i> = 2	<i>n</i> = 1
No impairment, <i>n</i> (%)	5 (38.5)	3 (30.0)	1 (50)	1 (100)
Gastritis, <i>n</i> (%)	5 (38.5)	4 (40.0)	1 (50)	0 (0)
Esophagitis, <i>n</i> (%)	1 (7.7)	1 (10.0)	0 (0)	0 (0)
Gastric fold atrophy, <i>n</i> (%)	1 (7.7)	1 (10.0)	0 (0)	0 (0)
Hiatal hernia, <i>n</i> (%)	1 (7.7)	1 (10.0)	0 (0)	0 (0)
High-resolution esophageal manometry				
<i>Motility alterations</i>	<i>n</i> = 20	<i>n</i> = 15	<i>n</i> = 3	<i>n</i> = 2
No impairment, <i>n</i> (%)	5 (25.0)	3 (20.0)	2 (66.7)	0 (0)
Hypercontractility tendency, <i>n</i> (%)	2 (10.0)	2 (13.3)	0 (0)	0 (0)
Tertiary waves, <i>n</i> (%)	1 (5.0)	0 (0.0)	1 (33.3)	0 (0)
≥50% ineffective waves, <i>n</i> (%)	4 (20.0)	3 (20.0)	0 (0)	1 (50)
Ineffective motility, <i>n</i> (%)	8 (40.0)	7 (46.7)	0 (0)	1 (50)
<i>Sphincter/GEJ alterations</i>				
No impairment, <i>n</i> (%)	17 (85.0)	12 (80.0)	3 (100)	2 (100)
Atypical LES dysfunction, <i>n</i> (%)	1 (5.0)	1 (6.7)	0 (0)	0 (0)
GEJ obstruction, <i>n</i> (%)	2 (10.0)	2 (13.3)	0 (0)	0 (0)
Hiatal hernia, <i>n</i> (%)	2 (10.0)	2 (13.3)	0 (0)	0 (0)
Esophageal 24-h pH	<i>n</i> = 20	<i>n</i> = 15	<i>n</i> = 3	<i>n</i> = 2
Pathological GER, <i>n</i> (%)	9 (45.0)	7 (46.7)	1 (33.3)	1 (50.0)

Abbreviations: AHT: arterial hypertension; CT, computed tomography; FENO: exhaled fraction of nitric oxide; FEV₁: forced expiratory volume in the first second; FVC: forced vital capacity; GEJ: gastroesophageal junction; GER: gastroesophageal reflux; ILO: inducible laryngeal obstruction; IgE: immunoglobulin E; kIU/L: kilo international units per litre; LES: lower esophageal sphincter; ppb: parts per billion; SD, standard deviation; UAO: upper airway obstruction.

^a Dermatophagoides Pteronyssinus and D. Farinae.

lelic expansion (50%; *n* = 2). The higher than expected prevalence of heterozygous (AAGGG)exp carriers is somewhat suggestive of a relationship with CC, although a more robust conclusions would require further studies.

Further evaluation of use of the Rydel-Seiffer fork for early detection of altered peripheral vibratory sensitivity seems appro-

priate, since 2 of the 6 patients with altered Rydel-Seiffer fork results had a positive result for early-stage CANVAS (biallelic (AAGGG)exp in RFC1, without neurological symptoms). The result of this simple and rapid test could serve as an early sign of CANVAS and enable patient selection for genetic screening, or, where a genetic study was not available, for referral to neurology.

Table 4
Chronic cough impact on quality of life: questionnaire results.

Domain	Total (n = 27)	(AAGGG)exp in <i>RFC1</i>		
		Without (n = 20)	Monoallelic (n = 5)	Biallelic (n = 2)
<i>Discrete Emotions Questionnaire (DEQ)</i>				
Anger, mean (SD)	3.5 (±1.9)	3.4 (±2.0)	3.1 (±1.6)	5.5 (±1.1)
Disgust, mean (SD)	2.7 (±1.7)	2.6 (±1.6)	2.5 (±1.8)	4.3 (±1.8)
Fear, mean (SD)	2.8 (±1.9)	2.8 (±1.7)	2.1 (±1.7)	4.3 (±3.9)
Anxiety, mean (SD)	3.8 (±1.8)	4.1 (±1.7)	2.6 (±1.9)	4.4 (±2.7)
Sadness, mean (SD)	2.6 (±1.8)	2.7 (±1.8)	2.2 (±2.2)	3.0 (±1.8)
Desire, mean (SD)	1.7 (±0.8)	1.6 (±0.8)	1.7 (±1.0)	2.0 (±1.0)
Relaxation, mean (SD)	1.9 (±1.4)	1.6 (±1.1)	3.4 (±1.8)	1.9 (±1.2)
Happiness, mean (SD)	1.3 (±1.0)	1.3 (±1.1)	1.4 (±0.5)	1.1 (±0.2)
<i>Leicester Cough Questionnaire (LCQ)</i>				
Physical, mean (SD)	5.2 (±3.1)	5.5 (±3.6)	5.0 (±1.1)	4.0 (±0.7)
Psychological, mean (SD)	4.2 (±1.8)	4.1 (±1.6)	4.9 (±2.6)	2.5 (±1.9)
Social, mean (SD)	4.1 (±1.6)	3.9 (±1.7)	4.9 (±1.1)	3.5 (±0.7)
Total, mean (SD)	12.4 (±4.8)	12.1 (±5.3)	14.8 (±2.8)	10.0 (±0.5)
<i>Cough Severity Diary (CSD)</i>				
Frequency, mean (SD)	4.1 (±2.4)	4.4 (±2.4)	2.8 (±2.0)	4.0 (±3.0)
Intensity, mean (SD)	3.9 (±2.5)	4.0 (±2.7)	3.3 (±1.7)	4.8 (3.2±)
Disruptiveness, mean (SD)	1.9 (±2.4)	2.2 (±2.6)	0.8 (±1.2)	2.3 (±2.5)
Total, mean (SD)	5.6 (±11.1)	6.6 (±12.8)	2.3 (±1.5)	4.0 (±3.0)
<i>EQ-5D-5L</i>				
Total, mean (SD)	0.9 (±0.1)	1.0 (±1.3)	0.9 (±0.1)	0.6 (±0.2)
VAS, mean (SD)	62.5 (±24.9)	59.5 (±27.9)	76 (±11.4)	57.5 (±3.5)

Better-to-worse scores:
DEQ = 1-7; EQ-5D-5L health state = 1 to <0; EQ-5D-5L VAS = 100-0; LCQ = 7-1 (total = 21-3); CSD = 1-10.

Abbreviations: EQ-5D-5L: European Quality of Life-5 Dimensions-5 Levels; VAS: visual analogue scale.

Because no statistically significant differences were found in the clinical or functional characteristics of patients with and without (AAGGG)exp in *RFC1*, we could not define in further detail which specific patients should undergo genetic testing. In the complementary tests, we only detected a statistically significant difference in relation to chest CT results: patients with no alteration more frequently presented with at least one (AAGGG)exp in *RFC1* ($p = 0.03$). Although differences in the GER tests were not statistically significant, the 2 patients with biallelic (AAGGG)exp had impaired esophageal motility, suggesting that further study is needed in this regard to understand the mechanisms underlying CC.

The questionnaires, which confirmed a poorer QoL that especially affected the psychosocial sphere, corroborate the results of previously published studies.²³

The main strength of our study is that it was supported by a multidisciplinary team of neurologists, geneticists, gastroenterologists, and pulmonologists. Limitations include the small sample size – due to the high cost associated with complementary testing and especially genetic studies of patients with CC – and the fact that the study was conducted in a single centre. Another limitation was not having access to long-read sequencing to determine if the heterozygous carrier of (AAGGG)exp/(AAAGG)exp had >500 repeats in the (AAAGG)exp allele. Likewise, we were unable to analyze the possible presence of recently described exceptionally pathogenic motifs associated with CANVAS (AGGGC, AAGGC y AGAGG), although no case has been described to date in Spain. Furthermore, patients with CC showing neurological symptoms compatible with CANVAS were not analyzed because this was a reason for exclusion, and a more exhaustive neurological study would possibly have identified other neurological causes of CC.

Conclusion

Genetic screening for (AAGGG)exp in *RFC1* should be considered in specialized CC consultations, especially of patients with RCC and UCC. Also meriting consideration in these consultations is use of the Rydel-Seiffer fork, as a low-cost, rapid, and simple complementary

test that could identify which patients with CC should be referred for neurological and/or genetic studies. Finally, all CC studies it is important to alert to possible symptoms indicative of CANVAS, in the interest of early diagnosis and of benefit for both the patient and the health system.

Authors' contributions

Substantial contributions to study conception and design of the study: EP, VP, LGQ, PG, LQ, FB, MR, ASC, ACL. Acquisition, analysis, and interpretation of data: EP. Drafting the article: EP, ACL. Revising the article critically for important intellectual content and final approval of the version to be submitted: all co-authors.

Funding

This research was supported by a grant from the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) [1144, 2021]. Also for this research, EP was supported by the Catalan Society of Pulmonology (SOCAP) [IIBSP-TOS-2020-143, 2022], LGQ and PG by the Instituto de Salud Carlos III and co-funded by EDRF/FEDER, 'Una manera de hacer Europa' under grant from CIBERER [ACCI ER21P1AC705, 2020], and ASC by a grant from the Spanish Ministry of Universities [FPU20/06692, 2020].

Conflicts of interests

EP has received, in the last 3 years, conference travel and attendance expenses from AstraZeneca, Sanofi, Gebro Pharma, Chiesi, FAES Farma, and GSK, and for talks at meetings sponsored by AstraZeneca and GSK, and has received funds/grants for research projects from state agencies, non-profit foundations, and GSK.

VP has received, in the last 3 years, honoraria for speaking at sponsored meetings from Astrazeneca, Boehringer-Ingelheim, Chiesi, Gebro, GSK, Luminova-Medwell, and Sanofi, has received assistance with travel expenses from Astrazeneca and Chiesi, and has acted as a consultant for Astrazeneca, Chiesi, GSK, and Menarini.

LQG has received conference travel and attendance expenses and fees for talks at meetings sponsored by PTC Therapeutics, and has received funds/grants for research projects from state agencies.

PG, LQ, FB, MR and **ASC** declare no conflicts of interest.

ACL has received, in the last 3 years, fees for talks at meetings sponsored by AstraZeneca, Zambón, Boehringer Ingelheim, Chiesi, SANOFI, GSK, MSD, Novartis, Orion Pharma, and Sanofi, has received travel and attendance expenses for conferences from Gebro, GSK, Novartis, AstraZeneca, and Sanofi, and has received funds/grants for research projects from several state agencies, non-profit foundations, and AstraZeneca and GSK.

Acknowledgements

The authors would like to thank Ailish M.J. Maher for translating and reviewing the article.

References

1. Irwin RS, Baumann MH, Bolser DC, Boulet LP, Braman SS, Brightling CE, et al. Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. *Chest*. 2006;129 Suppl.:1S–23S. http://dx.doi.org/10.1378/chest.129.1_suppl.1S.
2. Morice AH. Chronic cough: epidemiology. *Chron Respir Dis*. 2008;5:43–7. <http://dx.doi.org/10.1177/1479972307084252>.
3. Lai K, Chen R, Lin J, Huang K, Shen H, Kong L, et al. A prospective multicenter on causes of chronic cough in China. *Chest*. 2013;143:613–20. <http://dx.doi.org/10.1378/chest.12-0441>.
4. Song WJ, Chang YS, Faruqi S, Kim JY, Kang MG, Kim S, et al. The global epidemiology of chronic cough in adults: a systematic review and meta-analysis. *Eur Respir J*. 2015;45:1479–81. <http://dx.doi.org/10.1183/09031936.00218714>.
5. McGarvey L, Gibson PG. What is chronic cough? Terminology. *J Allergy Clin Immunol Pract*. 2019;7:1711–4. <http://dx.doi.org/10.1016/j.jaip.2019.04.012>.
6. Chung KF, McGarvey L, Mazzone S. Chronic cough and cough hypersensitivity syndrome. *Lancet Respir Med*. 2016;4:934–5. [http://dx.doi.org/10.1016/S2213-2600\(16\)30373-3](http://dx.doi.org/10.1016/S2213-2600(16)30373-3).
7. Kimber J, Mitchell D, Mathias CJ. Chronic cough in the Holmes-Adie syndrome: association in five cases with autonomic dysfunction. *J Neurol Neurosurg Psychiatry*. 1998;65:583–6. <http://dx.doi.org/10.1136/jnnp.65.4.583>.
8. Spring PJ, Kok C, Nicholson GA, Ing AJ, Spies JM, Bassett ML, et al. Autosomal dominant hereditary sensory neuropathy with chronic cough and gastro-oesophageal reflux: clinical features in two families linked to chromosome 3p22–p24. *Brain*. 2005;128 Pt 12:2797–810. <http://dx.doi.org/10.1093/brain/awh653>.
9. Dupré M, Hermann R, Froment Tilikete C. Update on cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome (CANVAS). *Cerebellum*. 2021;20:687–700. <http://dx.doi.org/10.1007/s12311-020-01192-w>.
10. Cortese A, Simone R, Sullivan R, Vandrovicova J, Tariq H, Yau WY, et al. Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia. *Nat Genet*. 2019;51:649–58. <http://dx.doi.org/10.1038/s41588-019-0372-4>.
11. Huin V, Coarelli G, Guemy C, Boluda S, Debs R, Mochel F, et al. Motor neuron pathology in CANVAS due to RFC1 expansions. *Brain*. 2022;145:2121–32. <http://dx.doi.org/10.1093/brain/awab449>.
12. Tatineni S, Jarrouj G, Gomez CM, Baird BJ. Characterization of a chronic cough in cerebellar ataxia, neuropathy, vestibular areflexia syndrome. *Laryngosc Investig Otolaryngol*. 2023;8:730–8. <http://dx.doi.org/10.1002/lio2.1067>.
13. Infante J, García A, Serrano-Cárdenas KM, González-Aguado R, Gazulla J, de Lucas EM, et al. Cerebellar ataxia, neuropathy, vestibular areflexia syndrome (CANVAS) with chronic cough and preserved muscle stretch reflexes: evidence for selective sparing of afferent Ia fibres. *J Neurol*. 2018;265:1454–62. <http://dx.doi.org/10.1007/s00415-018-8872-1>.
14. Szmulewicz DJ, McLean CA, MacDougall HG, Roberts L, Storey E, Halmagyi GM. CANVAS an update: clinical presentation, investigation and management. *J Vestib Res*. 2014;24(5–6):465–74. <http://dx.doi.org/10.3233/VES-140536>.
15. Cortese A, Reilly MM, Houlden H. RFC1 CANVAS/spectrum disorder. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. *GeneReviews*® [Internet]. Seattle (WA): University of Washington, Seattle; 2020. p. 1993–2023.
16. Sánchez-Tejerina D, Alvarez PF, Laínez E, Martínez VG, Santa-Cruz DI, Verduguer L, et al. RFC1 repeat expansions and cerebellar ataxia, neuropathy and vestibular areflexia syndrome: experience and perspectives from a neuromuscular disorders unit. *J Neurol Sci*. 2023;446:120565. <http://dx.doi.org/10.1016/j.jns.2023.120565>.
17. Palones E, Curto E, Plaza V, Gonzalez-Quereda L, Segarra-Casas A, Querol L, et al. Clinical and functional characteristics, possible causes, and impact of chronic cough in patients with cerebellar ataxia, neuropathy, and bilateral vestibular areflexia syndrome (CANVAS). *J Neurol*. 2023. <http://dx.doi.org/10.1007/s00415-023-12001-9>.
18. Magy L, Chazelas P, Richard L, Deschamps N, Frachet S, Vallat JM, et al. Early diagnosis in cerebellar ataxia, neuropathy, vestibular areflexia syndrome (CANVAS) by focusing on major clinical clues: beyond ataxia and vestibular impairment. *Biomedicine*. 2022;10:2046. <http://dx.doi.org/10.3390/biomedicine10082046>.
19. Benkirane M, Da Cunha D, Marelli C, Larriou L, Renaud M, Varilj J, et al. RFC1 nonsense and frameshift variants cause CANVAS: clues for an unsolved pathophysiology. *Brain*. 2022;145:3770–5. <http://dx.doi.org/10.1093/brain/awac280>.
20. Ronco R, Perini C, Currò R, Dominik N, Facchini S, Gennari A, et al. Truncating variants in RFC1 in cerebellar ataxia, neuropathy, and vestibular areflexia syndrome. *Neurology*. 2023;100:e543–54. <http://dx.doi.org/10.1212/WNL.0000000000201486>.
21. Arteche-López A, Avila-Fernandez A, Damian A, Soengas-Gonda E, de la Fuente RP, Gómez PR, et al. New Cerebellar Ataxia, Neuropathy, Vestibular Areflexia Syndrome cases are caused by the presence of a nonsense variant in compound heterozygosity with the pathogenic repeat expansion in the RFC1 gene. *Clin Genet*. 2023;103:236–41. <http://dx.doi.org/10.1111/cge.14249>.
22. Dominik N, Magri S, Currò R, Abati E, Facchini S, Corbetta M, et al. Normal and pathogenic variation of RFC1 repeat expansions: implications for clinical diagnosis. *Brain*. 2023;146:5060–9. <http://dx.doi.org/10.1093/brain/awad240>. Erratum in: *Brain*. 2024 Feb 1;147(2):e23.
23. Ueda N, Yakushiji A, Schelfhout J, Tokita S, Kubo T. Impact of refractory and unexplained chronic cough on disease burden: a qualitative study. *BMC Pulm Med*. 2022;22:372. <http://dx.doi.org/10.1186/s12890-022-02171-z>.
24. Chamberlain SA, Garrod R, Douiri A, Masefield S, Powell P, Bücher C, et al. The impact of chronic cough: a cross-sectional European survey. *Lung*. 2015;193:401–8. <http://dx.doi.org/10.1007/s00408-015-9701-2>.
25. Guilleminault L, Chazelas P, Melloni B, Magdelaine C, Villeneuve T, Brouquières D, et al. Repeat expansions of RFC1 in refractory chronic cough: a missing piece of the puzzle? *Chest*. 2023;163:911–5. <http://dx.doi.org/10.1016/j.chest.2022.11.014>.
26. Turner RD, Hiron B, Cortese A, Birring SS. Chronic cough as a genetic neurological disorder? Insights from cerebellar ataxia with neuropathy and vestibular areflexia syndrome (CANVAS). *Lung*. 2023;201:511–9. <http://dx.doi.org/10.1007/s00408-023-00660-4>.
27. Rydel A, Seiffer W. Examinations of feelings of vibrations or so-called “bonesensitivity” (pallaesthesia). *Arch Psychiatr Nervenkr*. 1903;37:488–536.
28. Morice AH, Millqvist E, Bięksiene K, Birring SS, Dipcinigaitis P, Domingo Ribas C, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. *Eur Respir J*. 2020;55:1901136. <http://dx.doi.org/10.1183/13993003.01136-2019>. Erratum in: *Eur Respir J*. 2020 Nov 19;56(5).
29. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al. ATS/ERS Task Force. General considerations for lung function testing. *Eur Respir J*. 2005;26:153–61. <http://dx.doi.org/10.1183/09031936.05.00034505>.
30. Stanojevic S, Kaminsky DA, Miller MR, Thompson B, Aliverti A, Barjaktarevic I, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. *Eur Respir J*. 2022;60:2101499. <http://dx.doi.org/10.1183/13993003.01499-2021>.
31. American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. *Am J Respir Crit Care Med*. 2005;171:912–30. <http://dx.doi.org/10.1164/rccm.200406-710ST>.
32. Gyawali CP, Kahrilas PJ, Savarino E, Zerbib F, Mion F, Smout AJPM, et al. Modern diagnosis of GERD: the Lyon Consensus. *Gut*. 2018;67:1351–62. <http://dx.doi.org/10.1136/gutjnl-2017-314722>.
33. Yadlapati R, Kahrilas PJ, Fox MR, Bredenoord AJ, Prakash Gyawali C, Roman S, et al. Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0©. *Neurogastroenterol Motil*. 2021;33:e14058. <http://dx.doi.org/10.1111/nmo.14058>. Erratum in: *Neurogastroenterol Motil*. 2022 Dec 5;:e14179.
34. Harmon-Jones C, Bastian B, Harmon-Jones E. The discrete emotions questionnaire: a new tool for measuring state self-reported emotions. *PLOS ONE*. 2016;11:e0159915. <http://dx.doi.org/10.1371/journal.pone.0159915>.
35. Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MD, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). *Thorax*. 2003;58:339–43. <http://dx.doi.org/10.1136/thorax.58.4.339>.
36. Muñoz G, Buxó M, de Gracia J, Oliveira C, Martínez-García MA, Giron R, et al. Validation of a Spanish version of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. *Chron Respir Dis*. 2016;13:128–36. <http://dx.doi.org/10.1177/1479972316632005>.
37. Vernon M, Kline Leidy N, Nacson A, Nelsen L. Measuring cough severity: development and pilot testing of a new seven-item cough severity patient-reported outcome measure. *Ther Adv Respir Dis*. 2010;4:199–208. <http://dx.doi.org/10.1177/1753465810372526>.
38. Ramos-Goñi JM, Pinto Prades JL, Oppe M, Cabasés Hita JM, Rivero-Arias O. Estimación del conjunto de valores para los estados de salud del EQ-5D-5L basados en las preferencias de la población española. Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad, Política Social e Igualdad. Servicio de Evaluación del Servicio Canario de la Salud; 2014. Informes de Evaluación de Tecnologías Sanitarias: SESCS N° 2010/05.
39. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res*. 2011;20:1727–36. <http://dx.doi.org/10.1007/s11136-011-9903-x>.